BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 25909634)

  • 41. Tolerability of low-dose sulfamethoxazole/trimethoprim for Pneumocystis jirovecii pneumonia prophylaxis in kidney transplant recipients.
    Zmarlicka M; Martin ST; Cardwell SM; Nailor MD
    Prog Transplant; 2015 Sep; 25(3):210-6. PubMed ID: 26308779
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Pneumocystis jirovecii pneumonia prophylaxis in immunocompromised patients with systemic autoimmune diseases.
    Braga BP; Prieto-González S; Hernández-Rodríguez J
    Med Clin (Barc); 2019 Jun; 152(12):502-507. PubMed ID: 30853123
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Pneumocystis in the era of prophylaxis: do the guidelines have to change?
    Nunes J; Issa N; Dupuis A; Accoceberry I; Pedeboscq S
    Infection; 2022 Aug; 50(4):995-1000. PubMed ID: 35274281
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Clinical efficacy of first- and second-line treatments for HIV-associated Pneumocystis jirovecii pneumonia: a tri-centre cohort study.
    Helweg-Larsen J; Benfield T; Atzori C; Miller RF
    J Antimicrob Chemother; 2009 Dec; 64(6):1282-90. PubMed ID: 19858161
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Risk factors for Pneumocystis jirovecii pneumonia in kidney transplant recipients and appraisal of strategies for selective use of chemoprophylaxis.
    de Boer MG; Kroon FP; le Cessie S; de Fijter JW; van Dissel JT
    Transpl Infect Dis; 2011 Dec; 13(6):559-69. PubMed ID: 21689251
    [TBL] [Abstract][Full Text] [Related]  

  • 46. No occurrence of Pneumocystis jiroveci (carinii) pneumonia in 120 adults undergoing myeloablative unrelated cord blood transplantation.
    Tomonari A; Takahashi S; Ooi J; Tsukada N; Konuma T; Kato S; Kasahara S; Iseki T; Tojo A; Asano S
    Transpl Infect Dis; 2008 Oct; 10(5):303-7. PubMed ID: 18564982
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The outcome of Pneumocystis carinii pneumonia in Danish patients with AIDS.
    Pedersen C; Lundgren JD; Nielsen T; Andersen WH
    Scand J Infect Dis; 1989; 21(4):375-80. PubMed ID: 2587939
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Pneumocystis prophylaxis and survival in patients with advanced human immunodeficiency virus infection treated with zidovudine. The Zidovudine Epidemiology Group.
    Chaisson RE; Keruly J; Richman DD; Moore RD
    Arch Intern Med; 1992 Oct; 152(10):2009-13. PubMed ID: 1417373
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Determining the Incidence of Pneumocystis Pneumonia in Patients With Autoimmune Blistering Diseases Not Receiving Routine Prophylaxis.
    Amber KT; Lamberts A; Solimani F; Agnoletti AF; Didona D; Euverman I; Cozzani E; Yueh LH; Di Zenzo G; Leshem YA; Mimouni D; Hertl M; Horvath B
    JAMA Dermatol; 2017 Nov; 153(11):1137-1141. PubMed ID: 28854309
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Prophylaxis against pneumocystis pneumonia in rheumatoid arthritis patients treated with b/tsDMARDs: insights from 3787 cases in the FIRST registry.
    Sonomoto K; Tanaka H; Nguyen TM; Yoshinari H; Nakano K; Nakayamada S; Tanaka Y
    Rheumatology (Oxford); 2022 May; 61(5):1831-1840. PubMed ID: 34382090
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Low incidence of pneumocystis pneumonia utilizing PCR-based diagnosis in patients with B-cell lymphoma receiving rituximab-containing combination chemotherapy.
    Barreto JN; Ice LL; Thompson CA; Tosh PK; Osmon DR; Dierkhising RA; Plevak MF; Limper AH
    Am J Hematol; 2016 Nov; 91(11):1113-1117. PubMed ID: 27472910
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Late-onset Pneumocystis jirovecii pneumonia post-fludarabine, cyclophosphamide and rituximab: implications for prophylaxis.
    Haeusler GM; Slavin MA; Seymour JF; Lingaratnam S; Teh BW; Tam CS; Thursky KA; Worth LJ
    Eur J Haematol; 2013 Aug; 91(2):157-63. PubMed ID: 23668894
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Twice weekly prophylaxis with trimethoprim/sulfamethoxazole for
    Awad M; Sierra CM; Mesghali E; Bahjri K
    J Oncol Pharm Pract; 2021 Dec; 27(8):1936-1939. PubMed ID: 33307970
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Predictors for failure of Pneumocystis carinii pneumonia prophylaxis. Multicenter AIDS Cohort Study.
    Saah AJ; Hoover DR; Peng Y; Phair JP; Visscher B; Kingsley LA; Schrager LK
    JAMA; 1995 Apr; 273(15):1197-202. PubMed ID: 7707627
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Pneumocystis carinii severe pneumonia among human immunodeficiency virus-infected children in Thailand: the effect of a primary prophylaxis strategy.
    Chokephaibulkit K; Wanachiwanawin D; Chearskul S; Wanprapa N; Unganont K; Tantinikorn W; Udompunthurak S
    Pediatr Infect Dis J; 1999 Feb; 18(2):147-52. PubMed ID: 10048687
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Intravenous pentamidine for Pneumocystis carinii/jiroveci pneumonia prophylaxis in pediatric transplant patients.
    Clark A; Hemmelgarn T; Danziger-Isakov L; Teusink A
    Pediatr Transplant; 2015 May; 19(3):326-31. PubMed ID: 25712369
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Is cotrimoxazole prophylaxis against Pneumocystis jirovecii pneumonia needed in patients with systemic autoimmune rheumatic diseases requiring immunosuppressive therapies?
    Pereda CA; Nishishinya-Aquino MB; Brito-García N; Díaz Del Campo Fontecha P; Rua-Figueroa I
    Rheumatol Int; 2021 Aug; 41(8):1419-1427. PubMed ID: 33656582
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Pneumocystis jirovecii pneumonia is rare in renal transplant recipients receiving only one month of prophylaxis.
    Anand S; Samaniego M; Kaul DR
    Transpl Infect Dis; 2011 Dec; 13(6):570-4. PubMed ID: 22093215
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Risk factors for Pneumocystis jirovecii pneumonia in patients with lymphoproliferative disorders.
    Obeid KM; Aguilar J; Szpunar S; Sharma M; del Busto R; Al-Katib A; Johnson LB
    Clin Lymphoma Myeloma Leuk; 2012 Feb; 12(1):66-9. PubMed ID: 22000698
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.